Fairholme Capital Management’s Pfizer PFE Stock Holding History

Fairholme Capital Management’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.56M	Buy	+231,000	New	+$6.04M	0.37%	8

Other funds holding PFE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Fairholme Capital Management's PFE Position: Q2 2026 in Review

Fairholme Capital Management opened a new position in Pfizer (PFE) in Q2 2026: 231,000 shares worth $5.56M. The stake represents 0.37% of the portfolio and ranks #8 among its holdings.

2,818 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

Fairholme Capital Management held 231,000 shares of Pfizer worth $5.56M as of Q2 2026.
Pfizer was a new Fairholme Capital Management position in Q2 2026.
Pfizer made up 0.37% of Fairholme Capital Management's portfolio in Q2 2026, its #8 holding.
2,818 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Fairholme Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.